Abstract
Immune therapeutics are revolutionizing cancer treatments. In tandem, new and confounding imaging characteristics have appeared that are distinct from those typically seen with conventional cytotoxic therapies. In fact, only 10% of patients on immunotherapy may show tumor shrinkage, typical of positive responses on conventional therapy. Conversely, those on immune therapies may initially demonstrate a delayed response, transient enlargement followed by tumor shrinkage, stable size, or the appearance of new lesions. New imaging response criteria, such as the immune-related Response Evaluation Criteria in Solid Tumors (irRECIST) and immune-related Response Criteria (irRC), are being implemented in many trials. However, FDA approval of emerging therapies, including immunotherapies, still relies on the current RECIST criteria. In this chapter, we review the traditional and new imaging response criteria for evaluation of solid tumors and briefly touch on some of the more commonly associated immunotherapy-induced adverse events.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Kwak JJ, Tirumani SH, Van den Abbeele AD, Koo PJ, Jacene HA. Cancer immunotherapy: imaging assessment of novel treatment response patterns and immune-related adverse events. Radiographics. 2015;35(2):424–37.
Nishino M, Tirumani SH, Ramaiya NH, Hodi FS. Cancer immunotherapy and immune-related response assessment: the role of radiologists in the new arena of cancer treatment. Eur J Radiol. 2015;84(7):1259–68.
Okada H, Weller M, Huang R, Finocchiaro G, Gilbert MR, Wick W, et al. Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol. 2015;16(15):e534–e42.
Wolchok JD, Hoos A, Day S, Weber JS, Hamid O, Lebbé C, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15(23):7412.
Tirkes T, Hollar MA, Tann M, Kohli MD, Akisik F, Sandrasegaran K. Response criteria in oncologic imaging: review of traditional and new criteria. Radiographics. 2013;33(5):1323–41.
Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47:207.
Organization. W.H. WHO handbook for reporting results of cancer treatment: offset publication no. 481979.
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.
Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference. J Hepatol. 2001;35(3):421–30.
for the Panel of Experts in HCCDCT, Di Bisceglie AM, Zhu AX, Kramer BS, Gores GJ, Talwalkar J, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Nat Cancer Inst. 2008;100(10):698–711.
Van den Abbeele AD, Badawi RD. Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). Eur J Cancer. 2002;38:S60–S5.
Pinker K, Riedl C, Weber WA. Evaluating tumor response with FDG PET: updates on PERCIST, comparison with EORTC criteria and clues to future developments. Eur J Nucl Med Mol Imaging. 2017;44(1):55–66.
Subbiah V, Chuang HH, Kairemo K, Gambhire D. Defining clinical response criteria and early response criteria for precision oncology: current state-of-the-art and future perspectives. Diagnostics (2075–4418). 2017;7(1):10.
Vossen JA, Buijs M, Kamel IR. Assessment of tumor response on MR imaging after locoregional therapy. Tech Vasc Interv Radiol. 2006;9(3):125–32.
Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(Suppl 1):122S–50S.
Ellingson BM, Wen PY, Cloughesy TF. Modified criteria for radiographic response assessment in glioblastoma clinical trials. Neurotherapeutics: J Am Soc Exp NeuroTherap. 2017;14(2):307–20.
Wen PY, Chang S, Van den Bent MJ, Vogelbaum MA, Macdonald DR, Lee EQ. Response assessment in neuro-oncology clinical trials. J Clin Oncol. 2017;35:2439.
Alexander BM, Brown PD, Ahluwalia MS, Aoyama H, Baumert BG, Chang SM, et al. Clinical trial design for local therapies for brain metastases: a guideline by the response assessment in neuro-oncology brain metastases working group. Lancet Oncol. 2018;19(1):e33–42.
Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579–86.
Ribas A, Chmielowski B, Glaspy JA. Do we need a different set of response assessment criteria for tumor immunotherapy? Clin Cancer Res. 2009;15(23):7116.
Nishino M, Gargano M, Suda M, Ramaiya NH, Hodi FS. Optimizing immune-related tumor response assessment: does reducing the number of lesions impact response assessment in melanoma patients treated with ipilimumab? J Immunother Cancer. 2014;2(1):17.
Aarntzen EHJG, Srinivas M, Radu CG, Punt CJA, Boerman OC, Figdor CG, et al. In vivo imaging of therapy-induced anti-cancer immune responses in humans. Cell Mol Life Sci. 2013;70(13):2237–57.
Somarouthu B, Lee SI, Urban T, Sadow CA, Harris GJ, Kambadakone A. Immune-related tumour response assessment criteria: a comprehensive review. Br J Radiol. 2018;91(1084):20170457.
Porcu M, Solinas C, Garofalo P, de Azambuja E, Scartozzi M, Willard-Gallo K, et al. Radiological evaluation of response to immunotherapy in brain tumors: where are we now and where are we going? Crit Rev Oncol Hematol. 2018;126:135–44.
Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017;18(3):e143–e52.
Srishti Abrol GT HA, Kotrotsou A, Alfaro-Munoz KD, de Groot JF, Zinn P, Colen RR. Radiomics differentiate between true progression and pseudo-progression in GBM patients: annual meeting of the American society of neuroradiology—ASNR. 2016.
Lambregts DMJ, Lalezari F, Kurilova I, RGH B-T, Trebeschi S, HJWL A, et al. Predicting response to cancer immunotherapy using non-invasive radiomic biomarkers. Ann Oncol. 2019;30(6):998.
El Naqa I, Ten Haken RK. Can radiomics personalise immunotherapy? Lancet Oncol. 2018;19(9):1138–9.
Abrol S, Kotrotsou A, Hassan A, Elshafeey N, Hassan I, Idris T, et al. Radiomic analysis of pseudo-progression compared to true progression in glioblastoma patients: a large-scale multi-institutional study. J Clin Oncol. 2017;35(15_suppl):2015.
Elshafeey N, Kotrotsou A, Giniebra Camejo D, Abrol S, Hassan I, El Salek K, et al. Multicenter study to demonstrate radiomic texture features derived from MR perfusion images of pseudoprogression compared to true progression in glioblastoma patients. J Clin Oncol. 2017;35(15_suppl):2016.
Abrol S, Kotrotsou A, Hassan A, Elshafeey N, Idris T, Manohar N, et al. Abstract 3040: radiomics discriminates pseudo-progression from true progression in glioblastoma patients: a large-scale multi-institutional study. Cancer Res. 2018;78(13 Supplement):3040.
Elakkad A, Hassan A, Kotrotsou A, Kumar AM, McDonald C, Kogias E, et al. 213 radiomic machine learning algorithms discriminate pseudo-progression from true progression in glioblastoma patients: a multi-institutional study. Neurosurgery. 2018;65(CN_suppl_1):119–20.
Weber JS, Dummer R, de Pril V, Lebbé C, Hodi FS, for the MDXI. Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab. Cancer. 2013;119(9):1675–82.
Barjaktarevic IZ, Qadir N, Suri A, Santamauro JT, Stover D. Organizing pneumonia as a side effect of ipilimumab treatment of melanoma. Chest. 2013;143(3):858–61.
Bronstein Y, Ng CS, Hwu P, Hwu W-J. Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti–CTLA-4 antibody therapy. Am J Roentgenol. 2011;197(6):W992–W1000.
Colen RR, Fujii T, Bilen MA, Kotrotsou A, Abrol S, Hess KR, et al. Radiomics to predict immunotherapy-induced pneumonitis: proof of concept. Investig New Drugs. 2018;36(4):601–7.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Ayoub, M., Eleneen, Y., Colen, R.R. (2020). Cancer Imaging in Immunotherapy. In: Naing, A., Hajjar, J. (eds) Immunotherapy. Advances in Experimental Medicine and Biology, vol 1244. Springer, Cham. https://doi.org/10.1007/978-3-030-41008-7_18
Download citation
DOI: https://doi.org/10.1007/978-3-030-41008-7_18
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-41007-0
Online ISBN: 978-3-030-41008-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)